PE20000058A1 - Nueva forma de la sal del acido maleico 5-[4-[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona - Google Patents

Nueva forma de la sal del acido maleico 5-[4-[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona

Info

Publication number
PE20000058A1
PE20000058A1 PE1998001233A PE00123398A PE20000058A1 PE 20000058 A1 PE20000058 A1 PE 20000058A1 PE 1998001233 A PE1998001233 A PE 1998001233A PE 00123398 A PE00123398 A PE 00123398A PE 20000058 A1 PE20000058 A1 PE 20000058A1
Authority
PE
Peru
Prior art keywords
etoxy
diona
thiazolidin
pyridyl
benzyl
Prior art date
Application number
PE1998001233A
Other languages
English (en)
Inventor
Michael John Sasse
David C Lee
Paul Davis James Blaclker
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20000058A1 publication Critical patent/PE20000058A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN HIDRATO DE LA SAL DEL ACIDO MALEICO DE 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA QUE SE CARACTERIZA a)POR SU CONTENIDO DE AGUA ENTRE 0,4% A 2,5% p/p; b)SU ESPECTRO INFRAROJO; c)SU PATRON DE DIFRACCION DE RAYOS X; d)POR SU ESPECTRO RAMAN; e)POR SU ESPECTRO DE RESONANCIA MAGNETICA NUCLEAR EN ESTADO SOLIDO. EL HIDRATO SE PRESENTA EN FORMA AISLADA, PURA, CRISTALINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE SE CARACTERIZA POR LA CRISTALIZACION DE LA SAL DE ACIDO MALEICO DE 5-[4-[2-PIRIDIL)AMINO)-ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA EN ETANOL QUE CONTIENE DE 15% A 25% EN VOLUMEN DE AGUA. EL HIDRATO TIENE ACTIVIDAD HIPOGLICEMICA E HIPOLIPIDEMICA Y PUEDE SER UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE LA DIABETES MELLITUS, CONDICIONES ASOCIADAS A LA DIABETES MELLITUS Y COMPLICACIONES DE LAS MISMAS
PE1998001233A 1997-12-16 1998-12-16 Nueva forma de la sal del acido maleico 5-[4-[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona PE20000058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726566.4A GB9726566D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
PE20000058A1 true PE20000058A1 (es) 2000-02-26

Family

ID=10823692

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001233A PE20000058A1 (es) 1997-12-16 1998-12-16 Nueva forma de la sal del acido maleico 5-[4-[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona

Country Status (35)

Country Link
EP (2) EP1040110A1 (es)
JP (1) JP2002508373A (es)
KR (1) KR100549142B1 (es)
CN (3) CN1281453A (es)
AP (1) AP1365A (es)
AR (1) AR017214A1 (es)
AU (1) AU1967999A (es)
BG (1) BG64988B1 (es)
BR (1) BR9813600A (es)
CA (1) CA2314107A1 (es)
CO (1) CO4980880A1 (es)
CZ (1) CZ299965B6 (es)
DZ (1) DZ2681A1 (es)
EA (1) EA004260B1 (es)
EG (1) EG22337A (es)
GB (1) GB9726566D0 (es)
HR (1) HRP20000408B1 (es)
HU (1) HUP0100509A3 (es)
IL (1) IL136424A (es)
IN (1) IN192487B (es)
MA (1) MA26580A1 (es)
MY (1) MY135612A (es)
NO (1) NO317254B1 (es)
OA (1) OA11766A (es)
PE (1) PE20000058A1 (es)
PL (1) PL341146A1 (es)
RS (1) RS50126B (es)
SA (1) SA99191115B1 (es)
SK (1) SK286618B6 (es)
TR (2) TR200001799T2 (es)
TW (1) TW509690B (es)
UA (1) UA72198C2 (es)
UY (2) UY25308A1 (es)
WO (1) WO1999031095A1 (es)
ZA (1) ZA9811506B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
OA11871A (en) * 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
PE20010045A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
ES2203453T3 (es) * 1999-04-23 2004-04-16 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
CZ20023502A3 (cs) * 2000-04-25 2003-06-18 Kyorin Pharmaceutical Co., Ltd. Nová stabilní krystalická forma thiazolidionového derivátu a způsob jeho přípravy
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
EP1322647A1 (en) * 2000-09-26 2003-07-02 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt and process for their preparation
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases

Also Published As

Publication number Publication date
EP1040110A1 (en) 2000-10-04
SK9172000A3 (en) 2001-01-18
IN192487B (es) 2004-04-24
DZ2681A1 (fr) 2004-06-20
AU1967999A (en) 1999-07-05
HUP0100509A2 (hu) 2002-05-29
HRP20000408A2 (en) 2000-08-31
ZA9811506B (en) 2000-11-06
CZ299965B6 (cs) 2009-01-07
TW509690B (en) 2002-11-11
KR100549142B1 (ko) 2006-02-03
UY25304A1 (es) 2000-12-29
MY135612A (en) 2008-05-30
SK286618B6 (sk) 2009-02-05
KR20010033141A (ko) 2001-04-25
CO4980880A1 (es) 2000-11-27
HUP0100509A3 (en) 2002-06-28
AR017214A1 (es) 2001-08-22
AP2000001831A0 (en) 2000-06-30
CA2314107A1 (en) 1999-06-24
IL136424A (en) 2003-12-10
EA200000654A1 (ru) 2000-12-25
CZ20002204A3 (cs) 2000-11-15
NO20003069D0 (no) 2000-06-15
MA26580A1 (fr) 2004-12-20
JP2002508373A (ja) 2002-03-19
RS50126B (sr) 2009-03-25
TR199802625A2 (xx) 1999-10-21
NO20003069L (no) 2000-06-15
CN1281453A (zh) 2001-01-24
TR200001799T2 (tr) 2001-01-22
UY25308A1 (es) 1999-07-19
WO1999031095A1 (en) 1999-06-24
BR9813600A (pt) 2000-10-10
UA72198C2 (en) 2005-02-15
OA11766A (en) 2005-07-19
GB9726566D0 (en) 1998-02-11
EG22337A (en) 2002-12-31
NO317254B1 (no) 2004-09-27
BG64988B1 (bg) 2006-11-30
EA004260B1 (ru) 2004-02-26
YU36300A (sh) 2004-03-12
CN101302215A (zh) 2008-11-12
AP1365A (en) 2005-01-26
TR199802625A3 (tr) 1999-10-21
BG104603A (en) 2001-03-30
PL341146A1 (en) 2001-03-26
IL136424A0 (en) 2001-06-14
HRP20000408B1 (en) 2008-04-30
CN101381367A (zh) 2009-03-11
EP1661895A1 (en) 2006-05-31
SA99191115B1 (ar) 2006-10-11

Similar Documents

Publication Publication Date Title
PE20000058A1 (es) Nueva forma de la sal del acido maleico 5-[4-[2-(n-metil-n-(2-piridil)amino)-etoxi]bencil]tiazolidin-2,4-diona
PE20000057A1 (es) Hidrato de la sal del acido maleico de la 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
AR016161A1 (es) Procedimiento para preparar un hidrato de la sal de acido maleico de 5-[4- [2-(n-metil-n(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona.
PE20010040A1 (es) Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
NO952573L (no) Blandinger for behandling av diabetiske komplikasjoner
PE20010045A1 (es) Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
AU754488B2 (en) Method for treating diabetes employing an aP2 inhibitor and combination
PE20000059A1 (es) Cristales de peptido-1 semejantes a glucagon
WO2001053237A3 (en) Production of monocycloalkyl aromatic compounds
JP2002508373A5 (es)
AU7847287A (en) Cloth towel dispenser and method for the operation thereof
YU40202A (sh) Novi derivati tiazolidindiona kao antidijabetički agensi
AR045230A1 (es) Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2- piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona y otro agente antidiabetico adicional; procedimiento para su preparacion y uso de 5-[4-[2-(metil-n-(2-piridil)-amino)-etoxi]- bencil]- tiazolidino-2,4-diona y otro agente antidiabetic
PE20010047A1 (es) Monohidrato de hidrocloruro de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
UY25101A1 (es) Método para el tratamiento de la diabetes mellitus y las condiciones asociadas
UY25048A1 (es) Composiciones para el tratamiento de la diabetes mellitus
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
ES2135353A1 (es) Utilizacion del 17beta-estradiol, sus analogos y derivados en el tratamiento de la diabetes mellitus y sus manifestaciones.
GJ Modelling oxygen-related structural changes in high-temperature superconductors
Yan et al. X-ray powder diffraction data and Rietveld refinement for NdCoGe sub 3
Muller et al. Energy Efficient Industrial Furnace Use by Consideration of Downtimes.(Retroactive Coverage)
IFF Pseudobinary phase diagrams of and
Kitada Superheated Competition of Materials--New Superconductors of Ceramics
Konnova et al. Utilization of Steam in the Process of Interaction Between Compounds of Nickel and Sodium Formate

Legal Events

Date Code Title Description
FC Refusal